Nefrocarnit (Levocarnitine)

Levocarnitine, the active ingredient in Nefrocarnit, is a mitochondrial support agent presented as an intravenous solution for parenteral use and is available in the European Union market. It is employed to correct carnitine deficiency and to support fatty‑acid metabolism in patients with certain metabolic or renal conditions.

GNH USA supplies Nefrocarnit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nefrocarnit is used to address disorders related to impaired carnitine metabolism and fatty‑acid oxidation.

Primary carnitine deficiency: restores intracellular carnitine levels to improve mitochondrial fatty‑acid oxidation. Secondary carnitine deficiency in renal dialysis patients: reduces muscle weakness and enhances energy metabolism. Inborn errors of metabolism affecting fatty‑acid oxidation: supports metabolic stability during acute decompensation.

Levocarnitine may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal discomfort - Headache or dizziness - Injection site pain or erythema - Mild fever or chills - Transient hypotension during infusion

Serious or Rare Side Effects: - Severe hypersensitivity reactions, including anaphylaxis - Seizures or convulsions - Cardiac arrhythmias - Metabolic acidosis - Hyperkalemia - Pulmonary edema

When using Nefrocarnit, clinicians should consider several safety measures.

Renal function monitoring: adjust therapy in patients with severe renal impairment. Seizure risk: use cautiously in individuals with a history of seizures. Allergy assessment: verify no known hypersensitivity to levocarnitine or formulation excipients. Concurrent metabolic disorders: monitor acid‑base status and electrolytes. Drug interaction vigilance: review concomitant medications that may affect carnitine metabolism. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levocarnitine can interact with several medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Valproic acid: may increase risk of hyperammonemia. - Warfarin: potential enhancement of anticoagulant effect. - Phenobarbital: may reduce levocarnitine plasma levels.

Moderate Interactions (Monitor Closely): - Insulin: levocarnitine may affect glucose metabolism. - Thyroid hormones: possible alteration of thyroid function tests. - Certain antibiotics (e.g., carbapenems): may interfere with carnitine transport.